Want to see VTRS full AI Analyst Report?
Top Page
Viatris
(NASDAQ:VTRS)
Select Model
Select Model
Rating:59Neutral
Price Target:
$17.00
▲(1.67% Upside)
Action:Reiterated
Date:08/07/26
VTRS scores 59 primarily because strong and improving cash generation plus a constructive earnings update (Q2 beat and raised full-year guidance) are tempered by weak reported profitability and earnings volatility. Technicals add a cautious tone (below short-term moving averages with RSI ~40), and valuation remains constrained by a negative P/E despite a moderate dividend yield.
Positive Factors
Strong cash generation
Robust operating and free cash flow provides internal funding for debt reduction, product investment and shareholder returns. The ability to generate substantial cash despite reported losses also indicates that the core commercial model and working-capital discipline remain valuable.
Negative Factors
Persistent bottom-line losses
Negative operating profit and net income weaken the quality and predictability of shareholder returns, even with strong cash flow. Multi-year earnings volatility and declining gross margin suggest that pricing, product mix or costs may continue to constrain sustainable GAAP profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash generation
Robust operating and free cash flow provides internal funding for debt reduction, product investment and shareholder returns. The ability to generate substantial cash despite reported losses also indicates that the core commercial model and working-capital discipline remain valuable.
Read all positive factors
Viatris Key Performance Indicators (KPIs)
Any
Revenue by Segment
Breaks down revenue across different business segments, highlighting which areas are driving growth and which may need strategic adjustments.
Breaks down revenue across different business segments, highlighting which areas are driving growth and which may need strategic adjustments.
Data provided by:
The Fly
The FlyViatris (VTRS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$19.20B
Dividend Yield2.85%
Average Volume (3M)9.48M
Price to Earnings (P/E)―
Beta (1Y)0.97
Revenue Growth4.92%
EPS Growth87.81%
CountryUS
Employees30,000
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.36
Shares Outstanding1,148,590,800
10 Day Avg. Volume8,837,165
30 Day Avg. Volume9,482,366
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.99
Price to Sales (P/S)1.02
P/FCF Ratio7.52
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$18.17Price Target Upside8.65% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)2.49
Revenue Forecast (FY)$14.78B
Viatris Business Overview & Revenue Model
Company Description
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The comp...
How the Company Makes Money
Viatris primarily makes money by selling prescription medicines worldwide, generating revenue when its products are purchased by wholesalers, distributors, pharmacies, hospital systems, and government or institutional buyers (with pricing and volu...
Viatris Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 09, 2026
Earnings Call Sentiment Positive
The call conveyed predominantly positive operational and strategic momentum: the company beat expectations in Q2 on revenue, EBITDA and EPS, raised full-year guidance across key metrics, showed margin improvement, strong cash generation, aggressive capital returns, meaningful pipeline and regulatory progress (Gwyn Lo approval, Nefecon topline, Phase III programs on track). Offsetting this, notable near-term challenges include Nashik manufacturing disruptions (with a $100–$150 million H2 revenue headwind), emerging markets supply constraints, competitive pressure in some developed-market products, and China procurement policy uncertainty that may moderate future growth. Overall, management framed the challenges as mostly short-term and fully considered in the updated guidance while emphasizing long-term growth opportunities and financial flexibility.Positive Updates
Total Revenue and Operational Growth
Q2 2026 total revenues of $3.8 billion, representing ~3.5% operational year-over-year revenue growth, driven by strength across multiple geographies and product categories.
Negative Updates
Nashik Facility Fire and FDA Inspection Observations
Intermittent manufacturing disruptions following a Q1 fire and an FDA inspection in May 2026 at the Nashik facility; company initiated a comprehensive remediation plan and expects supply impacts to be mostly short-term but material to H2 results.
Read all updates
Q2-2026 Updates
Positive
Negative
Total Revenue and Operational Growth
Q2 2026 total revenues of $3.8 billion, representing ~3.5% operational year-over-year revenue growth, driven by strength across multiple geographies and product categories.
Read all positive updates
Company Guidance
Viatris raised the midpoint of its 2026 guidance across all key metrics — at the midpoint the company now expects roughly 2% operational revenue growth, ~5% adjusted EBITDA growth and ~7% adjusted EPS growth versus 2025 — building on Q2 results of $3.8 billion revenue (+3.5% op), $1.2 billion adjusted EBITDA, $0.69 adjusted EPS and a 57.5% adjusted gross margin (Q2 free cash flow $329M, or $449M excluding transaction/restructuring costs and taxes). Management said full-year revenues are weighted to the second half (~51%), that adjusted EBITDA and EPS will be slightly lower in H2 while free cash flow is back‑end loaded, and that guidance already incorporates a $100–150M H2 revenue headwind from Nashik supply disruptions plus the expected Tyrvaya divestiture. Capital allocation metrics: ~$1.4B deployed year‑to‑date (including ~$550M returned to shareholders and ~$270M of buybacks), ~ $900M of maturing debt repaid, ~2.9x gross leverage (target range 2.8–3.2x), and approximately $1.6B of deployable capital remaining (including ~ $380M pretax Biocon proceeds). Segment-level 2026 expectations were provided: Greater China low double‑digit growth, developed markets roughly flat (North America slightly down), emerging markets low single‑digit growth and JANZ a low single‑digit decline.Viatris Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
52
Neutral
Cash Flow
71
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.74B | 14.30B | 14.74B | 15.43B | 16.26B | 17.89B |
| Gross Profit | 5.13B | 5.01B | 5.62B | 6.44B | 6.50B | 5.58B |
| EBITDA | 2.64B | -395.40M | 2.82B | 3.52B | 6.43B | 4.48B |
| Net Income | -410.70M | -3.51B | -634.20M | 54.70M | 2.08B | -1.27B |
Balance Sheet | ||||||
| Total Assets | 35.04B | 37.19B | 41.50B | 47.69B | 50.02B | 54.84B |
| Cash, Cash Equivalents and Short-Term Investments | 1.51B | 1.45B | 1.09B | 1.18B | 1.47B | 935.00M |
| Total Debt | 13.63B | 14.70B | 14.31B | 18.37B | 19.53B | 23.36B |
| Total Liabilities | 20.78B | 22.48B | 22.87B | 27.22B | 28.95B | 34.35B |
| Stockholders Equity | 14.26B | 14.71B | 18.64B | 20.47B | 21.07B | 20.49B |
Cash Flow | ||||||
| Free Cash Flow | 1.87B | 1.94B | 1.98B | 2.33B | 2.51B | 2.51B |
| Operating Cash Flow | 2.33B | 2.32B | 2.30B | 2.80B | 3.00B | 3.02B |
| Investing Cash Flow | -84.30M | -427.70M | 1.80B | -764.10M | 1.47B | -117.80M |
| Financing Cash Flow | -1.91B | -1.29B | -4.33B | -2.30B | -3.88B | -3.01B |
Viatris Technical Analysis
Positive
16.72
Price Trends
16.51
Positive
15.91
Positive
14.29
Positive
Market Momentum
-0.06
Negative
56.56
Neutral
91.27
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTRS, the sentiment is Positive. The current price of 16.72 is above the 20-day moving average (MA) of 16.56, above the 50-day MA of 16.51, and above the 200-day MA of 14.29, indicating a bullish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 56.56 is Neutral, neither overbought nor oversold. The STOCH value of 91.27 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VTRS.
Viatris Risk Analysis
Viatris disclosed 17 risk factors in its most recent earnings report. Viatris reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Viatris Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $1.74B | 15.44 | 19.19% | ― | 30.90% | ― | |
71 Outperform | $43.84B | 58.60 | 9.28% | ― | 4.33% | ― | |
62 Neutral | $10.41B | 29.76 | 8.88% | 0.95% | -6.76% | -44.35% | |
60 Neutral | $5.72B | 36.16 | -326.75% | ― | 9.28% | 4917.17% | |
59 Neutral | $19.20B | -46.81 | -2.79% | 2.78% | 4.92% | 87.81% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $2.01B | -1.18 | -55.97% | 11.50% | -4.18% | -2138.82% |
* Healthcare Sector Average
VTRS
Viatris
16.85
6.80
67.61%
RDY
Dr Reddy's Laboratories
12.22
-1.91
-13.53%
PRGO
Perrigo Company
14.76
-7.13
-32.57%
TEVA
Teva Pharmaceutical
37.92
19.88
110.20%
ANIP
ANI Pharmaceuticals
74.56
-17.97
-19.42%
AMRX
Amneal Pharmaceuticals
17.99
8.44
88.38%
Viatris Corporate Events
Business Operations and StrategyStock BuybackFinancial DisclosuresM&A Transactions
Viatris Lifts 2026 Outlook After Strong Second Quarter
Positive
Aug 6, 2026
Viatris reported its second-quarter 2026 results on August 6, 2026, posting total revenues of $3.76 billion, up 5% year over year, with operational growth of 3.5%, and an adjusted EBITDA of $1.2 billion, up 8% operationally, despite a U.S. GAAP ne...
Business Operations and StrategyPrivate Placements and Financing
Viatris Secures New ¥40 Billion Term Loan Facility
Positive
Jul 1, 2026
On July 1, 2026, Viatris Inc. entered into an amended and restated term loan credit agreement with a syndicate of lenders led by Mizuho Bank, establishing a ¥40 billion senior unsecured term loan facility to support general corporate purposes...
Business Operations and StrategyPrivate Placements and Financing
Viatris Issues €650 Million Senior Notes to Refinance Debt
Positive
Jun 18, 2026
On June 17, 2026, Viatris Inc. completed a €650 million public offering of 4.250% senior unsecured notes due 2033, guaranteed by key subsidiaries including Mylan Inc. and Utah Acquisition Sub Inc. The notes, issued under an existing indentur...
Private Placements and Financing
Viatris Issues €650 Million Senior Notes in Europe
Positive
Jun 15, 2026
On June 12, 2026, Viatris Inc. entered into an underwriting agreement with a syndicate of banks led by BNP Paribas, Citigroup Global Markets Limited and Goldman Sachs Co. LLC to issue €650 million of 4.250% senior notes due 2033. The notes ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.